Urate-lowering therapy for the prevention and treatment of gout flare

Jennifer A. Tilleman, Edward M. Desimone, Richard McAuliffe

Research output: Contribution to specialist publicationArticle

Abstract

Gout is one of the most common rheumatologic arthritic diseases in the United States. Preventing future gout attacks requires lowering serum urate levels to promote dissolution of urate crystals, which is accomplished by reducing the production of serum uric acid or promoting its excretion. Xanthene oxidase inhibitors (XOIs), including allopurinol and febuxostat, are first-line agents for the prevention of acute attacks. Probenecid, a uricosuric agent, is an appropriate adjunctive therapy or second-line agent when XOIs are contraindicated or poorly tolerated. Recently, several third-line agents (e.g., pegloticase, lesinurad) have become available for the treatment of refractory gout.

Original languageEnglish (US)
Pages33-37
Number of pages5
Volume42
No3
Specialist publicationU.S. Pharmacist
StatePublished - Mar 1 2017

All Science Journal Classification (ASJC) codes

  • Pharmacy
  • Pharmacology
  • Pharmaceutical Science

Fingerprint Dive into the research topics of 'Urate-lowering therapy for the prevention and treatment of gout flare'. Together they form a unique fingerprint.

  • Cite this